RU2010118481A - Амиды, применимые в качестве ингибиторов потенциалзависимых натриевых каналов - Google Patents
Амиды, применимые в качестве ингибиторов потенциалзависимых натриевых каналов Download PDFInfo
- Publication number
- RU2010118481A RU2010118481A RU2010118481/04A RU2010118481A RU2010118481A RU 2010118481 A RU2010118481 A RU 2010118481A RU 2010118481/04 A RU2010118481/04 A RU 2010118481/04A RU 2010118481 A RU2010118481 A RU 2010118481A RU 2010118481 A RU2010118481 A RU 2010118481A
- Authority
- RU
- Russia
- Prior art keywords
- ring
- hydrogen
- aliphatic group
- pain
- nitrogen
- Prior art date
Links
- 108010052164 Sodium Channels Proteins 0.000 title 1
- 102000018674 Sodium Channels Human genes 0.000 title 1
- 150000001408 amides Chemical class 0.000 title 1
- 230000001419 dependent effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 22
- 125000001931 aliphatic group Chemical group 0.000 claims abstract 21
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 17
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 17
- 239000001257 hydrogen Substances 0.000 claims abstract 17
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 13
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 13
- 229910052736 halogen Inorganic materials 0.000 claims abstract 11
- 150000002367 halogens Chemical class 0.000 claims abstract 11
- 125000004429 atom Chemical group 0.000 claims abstract 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 9
- 125000000464 thioxo group Chemical group S=* 0.000 claims abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract 7
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims abstract 2
- 208000002193 Pain Diseases 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 7
- 239000001301 oxygen Chemical group 0.000 claims 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 125000002950 monocyclic group Chemical group 0.000 claims 6
- 239000011593 sulfur Chemical group 0.000 claims 6
- 125000004043 oxo group Chemical group O=* 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 208000008035 Back Pain Diseases 0.000 claims 3
- 208000004296 neuralgia Diseases 0.000 claims 3
- 206010019233 Headaches Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 206010028836 Neck pain Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000004550 Postoperative Pain Diseases 0.000 claims 2
- 206010059604 Radicular pain Diseases 0.000 claims 2
- 208000008765 Sciatica Diseases 0.000 claims 2
- 208000005298 acute pain Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- -1 5-10- heterocyclyl Chemical group 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000019430 Motor disease Diseases 0.000 claims 1
- 206010061533 Myotonia Diseases 0.000 claims 1
- 206010033557 Palpitations Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000018912 cluster headache syndrome Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000001037 epileptic effect Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000004899 motility Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000015706 neuroendocrine disease Diseases 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97929207P | 2007-10-11 | 2007-10-11 | |
| US60/979,292 | 2007-10-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010118481A true RU2010118481A (ru) | 2011-11-20 |
Family
ID=40373424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010118481/04A RU2010118481A (ru) | 2007-10-11 | 2008-10-10 | Амиды, применимые в качестве ингибиторов потенциалзависимых натриевых каналов |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8389734B2 (enExample) |
| EP (1) | EP2212292B1 (enExample) |
| JP (1) | JP5436434B2 (enExample) |
| KR (1) | KR20100066583A (enExample) |
| CN (1) | CN101855210A (enExample) |
| AU (1) | AU2008310661A1 (enExample) |
| CA (1) | CA2701766A1 (enExample) |
| IL (1) | IL204977A0 (enExample) |
| MX (1) | MX2010003864A (enExample) |
| NZ (1) | NZ584474A (enExample) |
| RU (1) | RU2010118481A (enExample) |
| WO (1) | WO2009049181A1 (enExample) |
| ZA (1) | ZA201002471B (enExample) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2662223C2 (ru) * | 2013-01-31 | 2018-07-25 | Вертекс Фармасьютикалз Инкорпорейтед | Пиридонамиды в качестве модуляторов натриевых каналов |
| US10253054B2 (en) | 2013-12-13 | 2019-04-09 | Vertex Pharmaceuticals Incorporated | Prodrugs of pyridone amides useful as modulators of sodium channels |
| RU2742005C2 (ru) * | 2016-07-07 | 2021-02-01 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Способы получения 4-алкокси-3-(ацил или алкил)оксипиколинамидов |
| US11358977B2 (en) | 2017-05-16 | 2022-06-14 | Vertex Pharmaceuticals Incorporated | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
| RU2775673C2 (ru) * | 2015-09-11 | 2022-07-06 | Сумитомо Дайниппон Фарма Ко., Лтд. | Новое соединение бензимидазола и его медицинское применение |
| US11529337B2 (en) | 2018-02-12 | 2022-12-20 | Vertex Pharmaceuticals Incorporated | Method of treating pain |
| US11827627B2 (en) | 2021-06-04 | 2023-11-28 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
| US11834441B2 (en) | 2019-12-06 | 2023-12-05 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofurans as modulators of sodium channels |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109112126B (zh) * | 2010-06-23 | 2024-06-14 | 库尔纳公司 | 通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病 |
| WO2012004743A1 (en) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Benzenesulfonamides useful as sodium channel inhibitors |
| CA2804351A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
| EP2593431B1 (en) | 2010-07-12 | 2014-11-19 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
| EP2593428B1 (en) | 2010-07-12 | 2014-11-19 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
| EP2593427B1 (en) | 2010-07-12 | 2014-12-24 | Pfizer Limited | Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain |
| JP2013532184A (ja) * | 2010-07-12 | 2013-08-15 | ファイザー・リミテッド | 電位開口型ナトリウムチャネル阻害剤として有用なｎ−スルホニルベンズアミド誘導体 |
| US9656959B2 (en) | 2010-12-22 | 2017-05-23 | Purdue Pharma L.P. | Substituted pyridines as sodium channel blockers |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2922847A1 (en) | 2012-11-20 | 2015-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase |
| BR112015018284B1 (pt) * | 2013-01-31 | 2023-03-07 | Vertex Pharmaceuticals Incorporated | Amidas como moduladores de canais de sódio, seus usos, e composição farmacêutica |
| KR102226587B1 (ko) | 2013-01-31 | 2021-03-11 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 퀴놀린 및 퀴나졸린 아미드 |
| JP6337109B2 (ja) | 2013-07-19 | 2018-06-06 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ナトリウムチャネルの調節剤としてのスルホンアミド |
| CA2946378A1 (en) * | 2014-04-22 | 2015-10-29 | Q-State Biosciences, Inc. | Analysis of compounds for pain and sensory disorders |
| US10048275B2 (en) | 2015-03-13 | 2018-08-14 | Q-State Biosciences, Inc. | Cardiotoxicity screening methods |
| WO2016187543A1 (en) | 2015-05-21 | 2016-11-24 | Q-State Biosciences, Inc. | Optogenetics microscope |
| MX386261B (es) * | 2015-10-07 | 2025-03-18 | Univ Arizona | Inhibidores de sumoilacion de crmp2 y usos de los mismos |
| AU2018300150A1 (en) * | 2017-07-11 | 2020-01-30 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| SG11202100130QA (en) | 2018-07-09 | 2021-02-25 | Lieber Institute Inc | Pyridine carboxamide compounds for inhibiting nav1.8 |
| AU2019302534B2 (en) | 2018-07-09 | 2024-10-03 | Lieber Institute, Inc. | Pyridazine compounds for inhibiting NaV1.8 |
| CN110885328B (zh) * | 2018-09-10 | 2022-08-12 | 成都康弘药业集团股份有限公司 | 作为钠通道阻滞剂的磺酰胺类化合物及其用途 |
| WO2020092187A1 (en) * | 2018-11-02 | 2020-05-07 | Merck Sharp & Dohme Corp. | 2-amino-n-phenyl-nicotinamides as nav1.8 inhibitors |
| GEAP202315648A (en) | 2018-11-02 | 2023-07-25 | Merck Sharp & Dohme Llc | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors |
| WO2020146612A1 (en) * | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| WO2020146682A1 (en) * | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| CN112390745B (zh) * | 2019-08-19 | 2022-10-21 | 江苏恒瑞医药股份有限公司 | 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用 |
| KR20220101606A (ko) * | 2019-09-12 | 2022-07-19 | 상하이 제민케어 파마슈티칼스 컴퍼니 리미티드 | 피리딘 산질화물 및 이의 제조 방법과 용도 |
| CN113045487B (zh) * | 2019-12-27 | 2025-01-17 | 明慧医药（上海）有限公司 | 一种选择性钠通道调节剂及其制备和应用 |
| KR20230026404A (ko) | 2020-06-17 | 2023-02-24 | 머크 샤프 앤드 돔 엘엘씨 | Nav1.8 억제제로서의 2-옥소-옥사졸리딘-5-카르복스아미드 |
| US11802122B2 (en) | 2020-06-17 | 2023-10-31 | Merck Sharp & Dohme Llc | 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors |
| EP4334293A1 (en) | 2021-05-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors |
| WO2022256842A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
| US11999699B2 (en) | 2021-06-15 | 2024-06-04 | Grünenthal GmbH | Substituted pyrazole amides |
| JP2025513455A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| CN117586180A (zh) * | 2022-08-12 | 2024-02-23 | 广州费米子科技有限责任公司 | 用作电压-门控钠通道抑制剂的化合物 |
| EP4385980A1 (en) | 2022-12-14 | 2024-06-19 | Grünenthal GmbH | Indazoles as inhibitors of nav1.8 |
| AR131345A1 (es) | 2022-12-14 | 2025-03-12 | Gruenenthal Gmbh | SULFOXIMINAS COMO INHIBIDORES DE NaV1.8 |
| EP4385979A1 (en) | 2022-12-14 | 2024-06-19 | Grünenthal GmbH | Multicyclic inhibitors of nav1.8 |
| EP4385984A1 (en) | 2022-12-14 | 2024-06-19 | Grünenthal GmbH | Pyridine-n-oxides as inhibitors of nav1.8 |
| WO2024217344A1 (zh) * | 2023-04-19 | 2024-10-24 | 中国科学院上海药物研究所 | Nav1.8抑制剂及其制备方法和用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL105345C (enExample) * | 1957-05-29 | |||
| CA1135705A (en) | 1978-07-20 | 1982-11-16 | Jens-Uwe Bliesener | N-arylsulfonylpyrroles, their preparation, and therapeutic agents containing these compounds |
| US4228449A (en) * | 1978-12-26 | 1980-10-14 | Hughes Aircraft Company | Semiconductor diode array liquid crystal device |
| US6620849B2 (en) * | 2000-07-26 | 2003-09-16 | Icafen, Inc. | Potassium channel inhibitors |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| AU2002363250A1 (en) | 2001-11-01 | 2003-05-12 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
| SE0203752D0 (sv) | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| WO2004106324A1 (en) | 2003-05-27 | 2004-12-09 | E.I. Dupont De Nemours And Company | Azolecarboxamide herbicides |
| AU2004247559B2 (en) * | 2003-06-12 | 2009-08-27 | Astellas Pharma Inc. | Benzamide derivative or salt thereof |
| GB0317482D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
| KR20060073930A (ko) * | 2003-08-08 | 2006-06-29 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체 |
| JP2008519850A (ja) | 2004-11-10 | 2008-06-12 | シンタ ファーマシューティカルズ コーポレーション | Ｉｌ−１２調節化合物 |
| DOP2006000210A (es) | 2005-10-04 | 2007-06-15 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
| MX2008013194A (es) * | 2006-04-11 | 2008-12-01 | Vertex Pharma | Composiciones utiles como inhibidores de canales de sodio regulados por voltaje. |
| US8383734B2 (en) * | 2006-07-17 | 2013-02-26 | Syracuse University | Multi-solution bone cements and methods of making the same |
-
2008
- 2008-10-10 MX MX2010003864A patent/MX2010003864A/es not_active Application Discontinuation
- 2008-10-10 RU RU2010118481/04A patent/RU2010118481A/ru not_active Application Discontinuation
- 2008-10-10 EP EP08837614A patent/EP2212292B1/en active Active
- 2008-10-10 AU AU2008310661A patent/AU2008310661A1/en not_active Abandoned
- 2008-10-10 JP JP2010529092A patent/JP5436434B2/ja not_active Expired - Fee Related
- 2008-10-10 WO PCT/US2008/079544 patent/WO2009049181A1/en not_active Ceased
- 2008-10-10 US US12/249,251 patent/US8389734B2/en active Active
- 2008-10-10 CN CN200880115687A patent/CN101855210A/zh active Pending
- 2008-10-10 KR KR1020107010372A patent/KR20100066583A/ko not_active Withdrawn
- 2008-10-10 CA CA2701766A patent/CA2701766A1/en not_active Abandoned
- 2008-10-10 NZ NZ584474A patent/NZ584474A/en not_active IP Right Cessation
-
2010
- 2010-04-08 ZA ZA2010/02471A patent/ZA201002471B/en unknown
- 2010-04-08 IL IL204977A patent/IL204977A0/en unknown
-
2013
- 2013-01-23 US US13/747,716 patent/US8865771B2/en active Active
Cited By (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11673864B2 (en) | 2013-01-31 | 2023-06-13 | Vertex Pharmaceuticals Incorporated | Pyridone amides as modulators of sodium channels |
| US10087143B2 (en) | 2013-01-31 | 2018-10-02 | Vertex Pharmaceuticals Incorporated | Pyridone amides as modulators of sodium channels |
| US10738009B2 (en) | 2013-01-31 | 2020-08-11 | Vertex Pharmaceuticals Incorporated | Pyridone amides as modulators of sodium channels |
| RU2808424C2 (ru) * | 2013-01-31 | 2023-11-28 | Вертекс Фармасьютикалз Инкорпорейтед | Пиридонамиды в качестве модуляторов натриевых каналов |
| RU2662223C2 (ru) * | 2013-01-31 | 2018-07-25 | Вертекс Фармасьютикалз Инкорпорейтед | Пиридонамиды в качестве модуляторов натриевых каналов |
| US10253054B2 (en) | 2013-12-13 | 2019-04-09 | Vertex Pharmaceuticals Incorporated | Prodrugs of pyridone amides useful as modulators of sodium channels |
| RU2692766C1 (ru) * | 2013-12-13 | 2019-06-27 | Вертекс Фармасьютикалз Инкорпорейтед | Пролекарства пиридонамидов, применяемые в качестве модуляторов натриевых каналов |
| US10787472B2 (en) | 2013-12-13 | 2020-09-29 | Vertex Pharmaceuticals Incorporated | Prodrugs of pyridone amides useful as modulators of sodium channels |
| RU2811402C2 (ru) * | 2013-12-13 | 2024-01-11 | Вертекс Фармасьютикалз Инкорпорейтед | Пролекарства пиридонамидов, применяемые в качестве модуляторов натриевых каналов |
| US11773119B2 (en) | 2013-12-13 | 2023-10-03 | Vertex Pharmaceuticals Incorporated | Prodrugs of pyridone amides useful as modulators of sodium channels |
| RU2775673C2 (ru) * | 2015-09-11 | 2022-07-06 | Сумитомо Дайниппон Фарма Ко., Лтд. | Новое соединение бензимидазола и его медицинское применение |
| RU2742005C2 (ru) * | 2016-07-07 | 2021-02-01 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Способы получения 4-алкокси-3-(ацил или алкил)оксипиколинамидов |
| US11358977B2 (en) | 2017-05-16 | 2022-06-14 | Vertex Pharmaceuticals Incorporated | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
| US11529337B2 (en) | 2018-02-12 | 2022-12-20 | Vertex Pharmaceuticals Incorporated | Method of treating pain |
| RU2791534C2 (ru) * | 2019-01-04 | 2023-03-09 | Цзянсу Хэнжуй Медицин Ко., Лтд. | Производное 6-оксо-1,6-дигидропиридазина, способ его получения и его применение в медицине |
| US11834441B2 (en) | 2019-12-06 | 2023-12-05 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofurans as modulators of sodium channels |
| US11919887B2 (en) | 2019-12-06 | 2024-03-05 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofurans as modulators of sodium channels |
| US12247021B2 (en) | 2019-12-06 | 2025-03-11 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofurans as modulators of sodium channels |
| US11827627B2 (en) | 2021-06-04 | 2023-11-28 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
| US12258333B2 (en) | 2021-06-04 | 2025-03-25 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011500599A (ja) | 2011-01-06 |
| KR20100066583A (ko) | 2010-06-17 |
| WO2009049181A1 (en) | 2009-04-16 |
| MX2010003864A (es) | 2010-06-01 |
| EP2212292B1 (en) | 2012-12-05 |
| US8865771B2 (en) | 2014-10-21 |
| EP2212292A1 (en) | 2010-08-04 |
| JP5436434B2 (ja) | 2014-03-05 |
| IL204977A0 (en) | 2010-11-30 |
| CA2701766A1 (en) | 2009-04-16 |
| CN101855210A (zh) | 2010-10-06 |
| NZ584474A (en) | 2012-06-29 |
| US8389734B2 (en) | 2013-03-05 |
| ZA201002471B (en) | 2011-06-29 |
| AU2008310661A1 (en) | 2009-04-16 |
| US20130231370A1 (en) | 2013-09-05 |
| US20090118333A1 (en) | 2009-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010118467A (ru) | Ариламиды, пригодные в качестве ингибиторов потенциалзависимых натриевых каналов | |
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| JP2011500599A5 (enExample) | ||
| AU2012255759C1 (en) | Kinase inhibitors | |
| JP2011500600A5 (enExample) | ||
| JP2011500598A5 (enExample) | ||
| AU755694B2 (en) | 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof | |
| JP2020526561A5 (enExample) | ||
| HRP20200538T1 (hr) | Derivati pirimidina za liječenje virusnih infekcija | |
| JP2023515621A5 (enExample) | ||
| FI3853234T3 (fi) | Fuusioituja trisyklisiä rengasjohdannaisia SRC-homologia-2-fosfataasin estäjinä | |
| RU2011151835A (ru) | Пиразолопиримидины и родственные гетероциклы как ингибиторы киназ | |
| JP2023515617A5 (enExample) | ||
| SI3106463T1 (en) | Substituted pyrazolo(1,5-)pyrimidine compounds as trk kinase inhibitors | |
| RU2015143841A (ru) | Ингибиторы hdac | |
| RU2010136779A (ru) | Производные фенола и их применение в качестве ингибиторов ротамаз | |
| RU2009123930A (ru) | Химические соединения 637: пиридопиримидиндионы в качестве ингибиторов pde4 | |
| RU2009119181A (ru) | Гетероциклические соединения и их применение в качестве ингибиторов гликогенсинтаза-киназы-3 | |
| RU2010117156A (ru) | Гетероциклические соединения в качестве антагонистов crth2 рецептора | |
| JP2007521287A5 (enExample) | ||
| CA2446756A1 (en) | Thiazole compounds useful as inhibitors of protein kinase | |
| AR043673A1 (es) | Compuestos heterociclicos inhibidores no nucleosidos de la transcriptasa inversa i, preparacion de los mismos, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del sida | |
| WO2000064878A1 (de) | Cycloalkylsubstituierte benzimidazole und ihre verwendung als parp inhibitoren | |
| HRP20170104T1 (hr) | Derivati tipa azaindazola ili diazaindazola za liječenje boli | |
| RU2012116526A (ru) | Способы получения производных пиримидина, применимых в качестве ингибиторов протеинкиназы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20130109 |